SCHEMBL21952183

SCHEMBL21952183

CC(C)(C)CC1OCC2(CCN(C(=O)O)CC2)C1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21631653 0.80 — —
SCHEMBL16914477 0.80 — —
SCHEMBL20385857 0.73 USP2 (0.41) —
SCHEMBL20335660 0.70 OTUD7B (0.36) —
SCHEMBL21855018 0.68 TRPV1 (0.30) —
SCHEMBL23002557 0.66 USP2 (0.45) —
SCHEMBL18330214 0.66 USP2 (0.45) —
SCHEMBL16914257 0.66 USP2 (0.45) —
SCHEMBL16914102 0.65 NAMPT (0.33) —
SCHEMBL22799087 0.65 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199609-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2024-06-20 — — US disclosed
US-11498930-B2 Pyrimidine-fused cyclic compound, preparation method therefor and application thereof Blueray Therapeutics (Shanghai) Co., Ltd (CN) 2022-11-15 — — US disclosed
US-20210300919-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2021-09-30 — — US disclosed
US-10934285-B2 Compounds and compositions for inhibiting the activity of SHP2 NOVARTIS AG (CH) 2021-03-02 — — US disclosed
US-20210053989-A1 PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) 2021-02-25 — — US disclosed
EP-3468972-B1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2020-05-20 — — EP disclosed
Send feedback